Diplomat Pharmacy Inc. (DPLO) said Friday it was postponing the release of its fourth-quarter and full-year 2018 earnings as it and its auditors finalize the level of an impairment charge.
The company said its results and conference call have been pushed back to March 15. The company said it expects to file its 10-K for the fiscal year ended Dec. 31, 2018, soon after.
Results for January came in significantly below expectations -- that's just one of the reasons the company listed for also withdrawing the 2019 full-year outlook it provided less than a month ago. The company's outlook of 2018 revenue of $5.5 billion to $5.6 billion and 2018 adjusted EBITDA of $167 million to $170 million remains unchanged, as they are not impacted by the impairment charge, the pharmacy services company said in a release.
There are three buy ratings and eight hold ratings on the stock, according to Factset. The price target ranges from $14 to 24.